26 July 2017 - NICE has agreed a deal with Roche on its new follicular lymphoma treatment Gazyvaro, giving the drug up to four years to prove its value to patients.

The agreement has been hailed as a breakthrough by Roche, which has been at loggerheads with the cost effectiveness watchdog over its high priced cancer drugs many times in recent years.

Relations between Roche and other pharma companies and NICE and budget holder NHS England have thawed in recent times, however, with numerous access deals having already been agreed this year, including on Roche’s breast cancer treatment Kadcyla.

Read Pharmaphorum article